Evermay Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$53.2K Buy
107
+75
+234% +$33.2K 0.01% 350
2026
Q1
$14.3K Sell
32
-4
-11% -$1.86K ﹤0.01% 431
2025
Q4
$16.3K Sell
36
-57
-61% -$24.6K ﹤0.01% 404
2025
Q3
$36.4K Hold
93
﹤0.01% 343
2025
Q2
$41.4K Hold
93
0.01% 335
2025
Q1
$45.1K Hold
93
0.01% 331
2024
Q4
$37.5K Hold
93
0.01% 339
2024
Q3
$43.3K Sell
93
-213
-70% -$102K 0.01% 349
2024
Q2
$143K Hold
306
0.02% 223
2024
Q1
$128K Sell
306
-2
-0.6% -$845 0.02% 249
2023
Q4
$125K Buy
308
+2
+0.7% +$739 0.02% 222
2023
Q3
$106K Hold
306
0.02% 232
2023
Q2
$108K Hold
306
0.02% 232
2023
Q1
$96.4K Buy
306
+56
+22% +$16.8K 0.02% 242
2022
Q4
$72.2K Buy
+250
New +$76.2K 0.01% 259

Other funds holding VRTX

Evermay Wealth Management's VRTX Position: Q2 2026 in Review

Evermay Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 234% in Q2 2026, buying an estimated $33.2K and bringing the position to 107 shares worth $53.2K. The position accounts for 0.01% of the portfolio, ranked #350.

Evermay Wealth Management first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $143K in Q2 2024. 1,760 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Evermay Wealth Management held 107 shares of Vertex Pharmaceuticals worth $53.2K as of Q2 2026.
  • Evermay Wealth Management bought 75 Vertex Pharmaceuticals shares in Q2 2026, an estimated $33.2K.
  • Vertex Pharmaceuticals made up 0.01% of Evermay Wealth Management's portfolio in Q2 2026, its #350 holding.
  • Evermay Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Evermay Wealth Management's Vertex Pharmaceuticals position peaked at $143K in Q2 2024.
  • 1,760 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Evermay Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.